33 reports

  • Global Hepatitis Treatment B Market- By Type
  • North America Hepatitis Treatment B Market Overview

Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Hepatitis B Treatment Market by Type (Therapeutics and Vaccines), By End-User (Male and Female) for...

  • Hepatitis Treatment
  • World
  • Market Size
  • AbbVie Inc.
  • Bristol-Myers Squibb Company

Hepatitis C Therapies Market 2017-2027 ##.

  • Hepatitis Treatment
  • Therapy
  • Forecast
  • Market Shares
  • Market Size

Medicine; ##(##): ##-##.

  • Hepatitis Treatment
  • Market Size
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of ##. ##% During 2016 - 2024 ##.

  • Hepatitis Treatment
  • Therapy
  • World
  • Market Size

These results demonstrate that the triple combination of simeprevir, odalasvir and AL-## has the ability to shorten treatment duration, offer high efficacy and be generally well tolerated in those whose disease is caused by hepatitis C virus (HCV) genotype ## (GT##), one of

  • Hepatitis
  • Hepatitis Treatment
  • Pharmaceutical
  • United States
  • Achillion Pharmaceuticals, Inc.

In June, the company received approval from US FDA for Epclusa, for the treatment of adults with genotype ##-## chronic hepatitis C virus infection.

  • Hepatitis Treatment
  • HIV AIDS
  • United States
  • Company Financials
  • Gilead Sciences, Inc.
  • Gilead Sciences Enters into Licensing Agreement with Hetero Labs

Sovaldi is indicated for the treatment of genotype ##, ##, ## or ## chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen.

  • Hepatitis Treatment
  • Therapy
  • India
  • United States
  • Hetero Drugs Limited
  • LICENSING AGREEMENTS

The agreement also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.

  • Hepatitis Treatment
  • HIV Antiviral
  • Pharmaceutical
  • India
  • Mylan Inc.
  • PRODUCT PROFILE - PREZCOBIX

HIV MEDICINE; ##: ##-##.

  • Hepatitis Treatment
  • East Asia
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ViiV Healthcare Ltd.

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • United States
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • Market drivers

IFN has been considered a cornerstone for hepatitis treatment since its launch.

  • Hepatitis Treatment
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • Japan
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • GILEAD SCIENCES, INC.: SWOT ANALYSIS
  • GILEAD SCIENCES, INC.: COMPANY HISTORY

Gilead helped revolutionize the treatment of viral hepatitis, which affects approximately half a billion people worldwide, by providing medicines that cure chronic hepatitis C infection and manage chronic hepatitis B infection more effectively.

  • Hepatitis Treatment
  • Pharmaceutical
  • United States
  • Company
  • Gilead Sciences, Inc.

Associate Professor of Medicine Division of Gastroenterology Department of Medicine, Siriraj Hospital, Mahidol University will be available for interviews in advance via teleconference or onsite.

  • Hepatitis
  • Hepatitis Treatment
  • Infectious Disease
  • World
  • GlaxoSmithKline plc

" John' s scientific and business leadership has been notable for the development of Gilead' s portfolio of HIV and viral hepatitis medicines and commitment to worldwide access for patients.

  • Antiviral
  • Hepatitis Treatment
  • United States
  • Corporate Finance
  • Gilead Sciences, Inc.

Global Hepatitis B Virus (HBV) Market: ##-Year Demand Forecast (2016-2025) ##.

  • Hepatitis Treatment
  • United States
  • World
  • Forecast
  • Gilead Sciences, Inc.

CLINICAL TRIALS BY PHASE IN G## COUNTRIES HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* Country Name Pha

  • Clinical Trial
  • Hepatitis Treatment
  • Pharmaceutical
  • World
  • Product Initiative

Hepcvir-L is approved as a combination therapy for chronic hepatitis C genotype ## patients.

  • Hepatitis Treatment
  • Pharmaceutical
  • India
  • Company
  • Cipla Ltd
  • 3. Hepatitis C - Approved Drugs Sales & Forecast
  • The six main reasons for the high price-tags on promising new HCV drugs

This agreement allows Natco to expand access to these chronic hepatitis C medicines in ## developing countries.

  • Hepatitis Treatment
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation (LT) GDCT## NCT##, Gastrointestinal Hepatitis B, Liver Cirrhosis Completed Phase IV Observational hepatitis B immune globulin (human) Seoul St.

  • Cytokine
  • Digestive System Disorder
  • Hepatitis Treatment
  • Pharmaceutical
  • World
  • NOV 13, 2017: PHARMANIAGA, PHARCO AND DNDI SIGN AGREEMENT TO PROVIDE AFFORDABLE HEPATITIS C TREATMENT IN MALAYSIA
  • OCT 20, 2017: GILEAD ANNOUNCES PRESENTATION ON HARVONI AT THE LIVER MEETING 2017

Gilead Sciences, Inc. announced results from Phase ## and Phase ## studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead' s viral hepatitis

  • Hepatitis
  • Hepatitis Treatment
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • World
  • Forecast
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.

Hepatitis C

4546 5000 3864

Annals of Internal Medicine, ##(##), ##−## < DOI> ##. ##/ M##-##< / DOI>.

  • Hepatitis Treatment
  • European Union
  • Japan
  • North America
  • United States

Where relevant, CEAF medicines are funded in one of three ways: Group ##A: Drugs which are federally-funded and procured.

  • Hepatitis Treatment
  • Pharmaceutical
  • Brazil
  • Demand
  • GlaxoSmithKline plc

Australia was one of the first countries in the world to subsidize new medicines for all people over the age of ## who have chronic hepatitis C.

  • Antiviral
  • Hepatitis Treatment
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

GLOBAL HEPATITIS C VIRUS MARKET: THE COMPANY COULD BENEFIT FROM THE POTENTIAL GLOBAL HEPATITIS C VIRUS (HCV) MARKET.

  • Antiviral
  • Hepatitis Treatment
  • United States
  • Company
  • Gilead Sciences, Inc.
  • REGIONAL ACCESS TO HEPATITIS C TREATMENTS VARIES IN SPAIN
  • CREATIVE TAXATION MAY BE USED TO MITIGATE BUDGETARY IMPACT OF PAYING FOR NEW HEPATITIS C THERAPIES

The pricing and reimbursement of hepatitis C therapies has been in the spotlight since the launch of Sovaldi in the US in December 2013 at the price of $1,000 per pill. While Sovaldi's and Harvoni’s clinical effectiveness are undisputed, their high prices have prompted widespread criticism from payers, politicians, and patients due to the...

  • Hepatitis Treatment
  • Therapy
  • United States
  • Gilead Sciences, Inc.
  • Humana Inc.

The drug is indicated for the treatment of chronic hepatitis C virus genotype ## infection.

  • Hepatitis Treatment
  • United States
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • 3. Hepatitis C - Approved Drugs Sales & Forecast to

Global sales of Victrelis, an oral medicine for the treatment of chronic hepatitis C, were US$ ## Million in 2013, a decline of ##% compared with 2012 including a ##% unfavorable effect from foreign exchange.

  • Hepatitis Treatment
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • PRICE RESISTANCE: SOVALDI CASE STUDY

COUNCIL OF THE EUROPEAN UNION (2014) HIGH PRICE OF MEDICINES AGAINST HEPATITIS C.

  • Healthcare
  • Hepatitis Treatment
  • Pharmaceutical
  • Europe
  • EFPIA company